A5035158988- Virus-based gene therapy research
- CAR-T cell therapy research
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Cancer Immunotherapy and Biomarkers
- Asthma and respiratory diseases
- Viral gastroenteritis research and epidemiology
- Viral Infectious Diseases and Gene Expression in Insects
- Biochemical effects in animals
- Extracellular vesicles in disease
- Occupational and environmental lung diseases
- vaccines and immunoinformatics approaches
- Nanoplatforms for cancer theranostics
- Monoclonal and Polyclonal Antibodies Research
- Antifungal resistance and susceptibility
- Peptidase Inhibition and Analysis
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Viral Infections and Immunology Research
- Neuroblastoma Research and Treatments
- Animal Virus Infections Studies
- interferon and immune responses
- Pleural and Pulmonary Diseases
- Mast cells and histamine
- Herpesvirus Infections and Treatments
National Institute of Public Health
2015-2024
University of Padua
2022-2024
Warsaw University of Technology
2023-2024
Oncos Therapeutics (Finland)
2014-2024
Targovax (Norway)
2019-2024
Targovax (Finland)
2016-2022
National Academy of Medical Sciences of Ukraine
2019-2020
University of Helsinki
2015-2019
Roswell Park Comprehensive Cancer Center
2019
Ludwig Cancer Research
2019
Standard of care for cancer is commonly a combination surgery with radiotherapy or chemoradiotherapy. However, in some advanced patients this approach might still remaininefficient and may cause many side effects, including severe complications even death. Oncolytic viruses exhibit different anti-cancer mechanisms compared conventional therapies, allowing the possibility improved effect therapy. Chemotherapeutics combined oncolytic stronger cytotoxic responses oncolysis. Here, we have...
Malignant melanoma is an aggressive type of skin cancer whose incidence increasing globally. Although surgery effective in early stage melanoma, patients with advanced only have a 20% 5-year survival rate. Hence, combinations existing and new immunotherapy technologies immunotherapeutic agents are being evaluated. ONCOS-102 oncolytic adenovirus armed human GM-CSF Ad5/3 chimeric capsid. It has shown to be well tolerated phase I study (NCT01598129) wherein it induced antitumor immunity,...
The stimulation of the immune system using oncolytic adenoviruses (OAds) has attracted significant interest and several studies suggested that OAds immunogenicity might be important for their efficacy. Therefore, we developed a versatile rapid to adsorb tumor-specific major histocompatibility complex class I (MHC-I) peptides onto viral surface drive response toward tumor epitopes. By studying model epitope SIINFEKL, demonstrated peptide-coated OAd (PeptiCRAd) retains its infectivity cross...
Oncolytic viruses (OV) are engineered to infect, replicate in and kill cancer cells. Currently, the OV therapeutic approach is mainly restricted neoplasia amenable direct local administration of viral particles, while possibility a systemic delivery cancer-tropic would extend application treatment metastatic neoplasia. Herein, we applied vivo/ex vivo imaging demonstrate that tropism achieved when encapsulated inside extracellular vesicles (EV) administered intravenously (i.v.), but not...
Extracellular vesicles (EVs) are naturally occurring cargo delivery that have recently received considerable attention for their roles in intercellular communication many physiological and pathological processes, including tumourigenesis. EVs generated by different tissues demonstrated specific homing: particular, cancer-derived showed a selective tropism the tumor tissue from which originated. For this property, been proposed as drug tools anti-cancer therapies, although limited knowledge...
Malignant mesothelioma (MM) is a rare cancer type caused mainly by asbestos exposure. The median overall survival time of patient less than 1‐year from diagnosis. Currently there are no curative treatment modalities for malignant mesothelioma, however treatments such as surgery, chemotherapy and radiotherapy can help to improve prognosis increase life expectancy. Pemetrexed‐Cisplatin the only standard care (SoC) but PFS/OS (progression‐free survival/overall survival) initiation up 12 months....
Abstract Melanoma, an immunogenic tumor, is the first indication where oncolytic viruses are now becoming part of clinical practice. ONCOS‐102, a transgened adenovirus, has shown to act as primer relevant tumor targeting immune cells both in preclinical and melanoma studies. Strategies augment its effectiveness warrant investigation. Combination therapy ONCOS‐102 with checkpoint inhibitor (CPI) pembrolizumab was evaluated quasi‐human animal model, humanized NOG mouse model. A dosing schedule...
Triple-negative breast cancer (TNBC) is considered one of the most incurable malignancies due to its clinical characteristics, including high invasiveness, metastatic potential, proneness relapse, and poor prognosis. Therefore, it remains a critical unmet medical need. On other hand, delivery efficiency continues reduce efficacy anti-cancer therapeutics developed against solid tumours using various strategies, such as genetically engineered oncolytic vectors used nanocarriers. The study was...
Oncolytic viruses are able to specifically replicate, infect, and kill only cancer cells. Their combination with chemotherapeutic drugs has shown promising results due the synergistic action of virus drugs; combinatorial therapy is considered a potential clinically relevant approach for cancer. In this study, we optimized strategy absorb peptides on viral capsid, based electrostatic interaction, used deliver an active antitumor drug. We L-carnosine, naturally occurring histidine dipeptide...
Despite new therapies, the estimated 229 875 women living with ovarian cancer have a 5-year survival rate of 47.6%. This cavity-localized lends itself to local administration modalities, such as oncolytic adenovirus (Ad) Ad5/3-D24-granulocyte-macrophage colony-stimulating factor virus (ONCOS-102). Its repeated patient chemotherapy-refractory induced CD8+ antitumor immune responses overall reaching 40 months. Here we probe dominant receptor used by ONCOS-102 in four established epithelial...
Cancer cells employ various mechanisms to evade and suppress anti-cancer immune responses generating a "cold" immunosuppressive tumour microenvironment. Oncolytic viruses are promising tool convert immunosuppression immunomodulation improve the efficacy of cancer treatment. Emerging preclinical clinical findings confirm that oncolytic act in multimodal scheme, triggering lyses, immunogenic cell death finally inducing responses. In this paper, we tested local administration novel adenovirus...
Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor prognosis. As the available therapeutic options show lack of efficacy, novel strategies are urgently needed. Given its T-cell infiltration, we hypothesized that MPM suitable target for cancer vaccination. To date, research on has focused identification molecular signatures to better classify and characterize disease, little known about targets engage cytotoxic (CD8+) T cells. In this study investigate immunopeptidomic...
The purpose of this work was to carry out preclinical toxicity and bio-distribution studies required for regulatory approval a clinical trial application Phase I ONCOS-102 (Ad5/3-D24-GM-CSF) therapy advanced cancers (NCT01598129). study design, route administration dosage differs from the protocol in more detail, investigate toxicological profile treatment animal model. carried 300 hamsters divided into nine test groups–three groups six analysis toxicity. Hamsters received by intracardial,...
Oncolytic adenoviral immunotherapy activates the innate immune system with subsequent induction of adaptive tumor‐specific responses to fight cancer. Hence, oncolytic viruses do not only eradicate cancer cells by direct lysis, but also generate antitumor response, allowing for long‐lasting control and tumor reduction. Their therapeutic effect can be further enhanced arming adenovirus costimulatory transgenes and/or coadministration other therapies. ONCOS‐102 has already been found well...
In oncolytic virotherapy, the ability of virus to activate immune system is a key attribute with regard long-term antitumor effects. Vaccinia viruses bear one strongest activities among all viruses. However, its capacity for stimulation immunity not optimal, mainly due immunosuppressive nature. To overcome this problem, we developed an VV that expresses intracellular pattern recognition receptor DNA-dependent activator IFN-regulatory factors (DAI) boost innate and adaptive cells in tumor. We...
Despite significant advances in chemotherapy, the overall prognosis of hepatocellular carcinoma (HCC) remains extremely poor. HCC targeting strategies were combined with tumor cell cytotoxicity oncolytic viruses (OVs) to develop a more efficient and selective therapeutic system. OVs coated polygalactosyl-b-agmatyl diblock copolymer (Gal32-b-Agm29), high affinity for asialoglycoprotein receptor (ASGPR) expressed on liver surface, exploiting electrostatic interaction positively charged...
Tolerance toward tumor antigens, which are shared by normal tissues, have often limited the efficacy of cancer vaccines. However, wild type epitopes can be tweaked to activate cross-reactive T-cell clones, resulting in antitumor activity. The design these analogs (i.e., heteroclitic peptides) difficult and time-consuming since no automated silico tools available. Hereby we describe development an framework improve selection peptides. Epitope Discovery Improvement System (EDIS) was first...